hydroxyurea has been researched along with oxadiazoles in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chattopadhyay, A; Chaudhuri, U; Dasgupta, AK; Lahiri, P | 1 |
| Canalli, AA; Conran, N; Costa, FF; Franco-Penteado, CF; Saad, ST | 1 |
| Biraboneye, AC; Kraus, JL; Madonna, S; Maher, P | 1 |
3 other study(ies) available for hydroxyurea and oxadiazoles
| Article | Year |
|---|---|
Platelet aggregation profile as a marker of hydroxyurea bioavailability through nitric oxide generation in chronic myelogenous leukemia.
Topics: Adult; Biological Availability; Blood Platelets; Cyclic GMP; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitric Oxide; Oxadiazoles; Platelet Aggregation; Quinoxalines; Time Factors | 2006 |
Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.
Topics: Adult; alpha-Thalassemia; Anemia, Sickle Cell; CD11a Antigen; CD11b Antigen; Cell Adhesion; Cyclic GMP; Endothelial Cells; Female; Fibronectins; Humans; Hydrazines; Hydroxyurea; Integrin alpha4; Intercellular Adhesion Molecule-1; Male; Middle Aged; Neutrophils; Nitric Oxide; Nitric Oxide Donors; Nitroprusside; Oxadiazoles; Pyrazoles; Pyridines; Quinoxalines; Sickle Cell Trait | 2008 |
Neuroprotective effects of N-alkyl-1,2,4-oxadiazolidine-3,5-diones and their corresponding synthetic intermediates N-alkylhydroxylamines and N-1-alkyl-3-carbonyl-1-hydroxyureas against in vitro cerebral ischemia.
Topics: Animals; Brain Ischemia; Cell Line; Extracellular Signal-Regulated MAP Kinases; Hydroxylamines; Hydroxyurea; JNK Mitogen-Activated Protein Kinases; Mice; Neuroprotective Agents; Oxadiazoles; p38 Mitogen-Activated Protein Kinases | 2010 |